Genovis AB (publ.) (GENO.ST)
SEK 25.0
(2.04%)
SEK 25.0
(2.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 64.57 Million SEK | 118.82% |
| 2022 | 14.9 Million SEK | 7.5% |
| 2021 | 30.37 Million SEK | 119.88% |
| 2020 | 8.57 Million SEK | -27.62% |
| 2019 | 17.02 Million SEK | 178.92% |
| 2018 | 2.07 Million SEK | 198.02% |
| 2017 | -6.22 Million SEK | 66.48% |
| 2016 | -13.47 Million SEK | 20.9% |
| 2015 | -18.5 Million SEK | -23.33% |
| 2014 | -19.04 Million SEK | -28.66% |
| 2013 | -15.03 Million SEK | 1.0% |
| 2012 | -18.73 Million SEK | -20.23% |
| 2011 | -12.43 Million SEK | -22.73% |
| 2010 | -10.13 Million SEK | 10.37% |
| 2009 | -11.3 Million SEK | 38.74% |
| 2008 | -18.44 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 5.25 Million SEK | -69.63% |
| 2024 Q1 | 17.3 Million SEK | 173.7% |
| 2023 Q1 | 45.08 Million SEK | 9614.37% |
| 2023 Q2 | 7.68 Million SEK | -82.95% |
| 2023 Q3 | 7.55 Million SEK | -1.72% |
| 2023 FY | - SEK | 118.82% |
| 2023 Q4 | 5.44 Million SEK | -27.89% |
| 2022 Q2 | 2.1 Million SEK | -82.0% |
| 2022 FY | - SEK | 7.5% |
| 2022 Q3 | 6.99 Million SEK | 231.77% |
| 2022 Q4 | -473.9 Thousand SEK | -106.77% |
| 2022 Q1 | 11.71 Million SEK | -41.19% |
| 2021 Q3 | 2.2 Million SEK | -21.16% |
| 2021 Q4 | 19.92 Million SEK | 804.83% |
| 2021 FY | - SEK | 119.88% |
| 2021 Q1 | 1.95 Million SEK | -73.31% |
| 2021 Q2 | 2.79 Million SEK | 42.65% |
| 2020 Q3 | 3.26 Million SEK | 8684.21% |
| 2020 Q4 | 7.33 Million SEK | 124.92% |
| 2020 Q1 | 1.31 Million SEK | 167.12% |
| 2020 FY | - SEK | -27.62% |
| 2020 Q2 | -38 Thousand SEK | -102.89% |
| 2019 FY | - SEK | 178.92% |
| 2019 Q4 | 491.91 Thousand SEK | -93.84% |
| 2019 Q1 | 2.69 Million SEK | 40.85% |
| 2019 Q2 | 2.39 Million SEK | -11.32% |
| 2019 Q3 | 7.98 Million SEK | 234.18% |
| 2018 Q2 | -595 Thousand SEK | -3618.75% |
| 2018 FY | - SEK | 198.02% |
| 2018 Q4 | 1.91 Million SEK | 9.52% |
| 2018 Q3 | 1.74 Million SEK | 393.61% |
| 2018 Q1 | -16 Thousand SEK | 97.22% |
| 2017 FY | - SEK | 66.48% |
| 2017 Q4 | -574.99 Thousand SEK | 55.74% |
| 2017 Q2 | -1.62 Million SEK | 35.91% |
| 2017 Q1 | -2.53 Million SEK | -28.44% |
| 2017 Q3 | -1.29 Million SEK | 20.01% |
| 2016 FY | - SEK | 20.9% |
| 2016 Q4 | -1.97 Million SEK | -166.24% |
| 2016 Q2 | -7.62 Million SEK | -143.4% |
| 2016 Q1 | -3.13 Million SEK | 1.2% |
| 2016 Q3 | -741 Thousand SEK | 90.29% |
| 2015 Q3 | -2.33 Million SEK | 52.64% |
| 2015 Q4 | -3.17 Million SEK | -36.14% |
| 2015 FY | - SEK | -23.33% |
| 2015 Q1 | -4.66 Million SEK | 17.02% |
| 2015 Q2 | -4.92 Million SEK | -5.42% |
| 2014 Q3 | -5.27 Million SEK | -16.37% |
| 2014 FY | - SEK | -28.66% |
| 2014 Q1 | -3.6 Million SEK | 32.17% |
| 2014 Q2 | -4.53 Million SEK | -25.8% |
| 2014 Q4 | -5.62 Million SEK | -6.6% |
| 2013 Q1 | -3.73 Million SEK | 53.85% |
| 2013 FY | - SEK | 1.0% |
| 2013 Q4 | -5.31 Million SEK | -110.67% |
| 2013 Q3 | -2.52 Million SEK | 26.98% |
| 2013 Q2 | -3.45 Million SEK | 7.57% |
| 2012 FY | - SEK | -20.23% |
| 2012 Q2 | -4.08 Million SEK | -11.52% |
| 2012 Q3 | -2.89 Million SEK | 29.11% |
| 2012 Q4 | -8.09 Million SEK | -179.73% |
| 2012 Q1 | -3.66 Million SEK | -9.99% |
| 2011 Q1 | -3.23 Million SEK | -3.94% |
| 2011 Q2 | -3.08 Million SEK | 4.73% |
| 2011 Q3 | -2.78 Million SEK | 9.85% |
| 2011 Q4 | -3.32 Million SEK | -19.72% |
| 2011 FY | - SEK | -22.73% |
| 2010 Q2 | -3.36 Million SEK | -67.55% |
| 2010 FY | - SEK | 10.37% |
| 2010 Q1 | -2 Million SEK | 29.55% |
| 2010 Q4 | -3.11 Million SEK | -20.88% |
| 2010 Q3 | -2.57 Million SEK | 23.44% |
| 2009 Q3 | -2.75 Million SEK | -6.51% |
| 2009 Q1 | -3.11 Million SEK | 0.0% |
| 2009 FY | - SEK | 38.74% |
| 2009 Q4 | -2.85 Million SEK | -3.7% |
| 2009 Q2 | -2.58 Million SEK | 17.16% |
| 2008 FY | - SEK | 0.0% |
| 2008 Q1 | -4.67 Million SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 127.175% |
| Ziccum AB (publ) | -20.34 Million SEK | 417.432% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | -3228500.0% |
| BioArctic AB (publ) | 275.38 Million SEK | 76.552% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | 3204.423% |
| Mendus AB (publ) | -97.84 Million SEK | 165.993% |
| Intervacc AB (publ) | -68.98 Million SEK | 193.61% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 580.768% |
| Active Biotech AB (publ) | -43.88 Million SEK | 247.132% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | -105.617% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 217.819% |
| Aptahem AB (publ) | -10 Million SEK | 745.125% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 120.34% |
| Kancera AB (publ) | -61.88 Million SEK | 204.335% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | -459.113% |
| Fluicell AB (publ) | -25.91 Million SEK | 349.178% |
| Saniona AB (publ) | -69.69 Million SEK | 192.649% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 633.477% |
| Biovica International AB (publ) | -119.5 Million SEK | 154.032% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 252.927% |
| AcouSort AB (publ) | -16.7 Million SEK | 486.589% |
| Xintela AB (publ) | -53.47 Million SEK | 220.761% |
| Abliva AB (publ) | -93.6 Million SEK | 168.981% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 120.236% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 341.093% |
| OncoZenge AB (publ) | 7.26 Million SEK | -788.687% |
| Amniotics AB (publ) | -27.14 Million SEK | 337.896% |
| 2cureX AB (publ) | -35.13 Million SEK | 283.777% |
| CombiGene AB (publ) | -35.33 Million SEK | 282.737% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 554.189% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 117.556% |
| Camurus AB (publ) | 562.54 Million SEK | 88.521% |
| Corline Biomedical AB | -1.69 Million SEK | 3918.569% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 137.255% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 274.406% |
| I-Tech AB | 30.34 Million SEK | -112.793% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 109.037% |
| Cyxone AB (publ) | -20.41 Million SEK | 416.312% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 163.026% |
| Biosergen AB | 228 Thousand SEK | -28221.053% |
| Cantargia AB (publ) | -284.31 Million SEK | 122.711% |
| NextCell Pharma AB | -40.98 Million SEK | 257.55% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 138.025% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 477.956% |
| Nanologica AB (publ) | -62.11 Million SEK | 203.949% |
| SynAct Pharma AB | -222.7 Million SEK | 128.995% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 247.22% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | -20769.194% |
| LIDDS AB (publ) | -39.67 Million SEK | 262.773% |
| Lipum AB (publ) | -37.11 Million SEK | 273.959% |
| BioInvent International AB (publ) | -312.7 Million SEK | 120.649% |
| Alzinova AB (publ) | 41.99 Thousand SEK | -153646.518% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 127.878% |
| Pila Pharma AB (publ) | -8.81 Million SEK | 832.734% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 156.195% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 429.802% |
| Simris Alg AB (publ) | -22.36 Million SEK | 388.745% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 145.844% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 122.895% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 159.482% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 663.013% |